Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.986477DOI Listing

Publication Analysis

Top Keywords

efficacy side-effects
4
side-effects decitabine
4
decitabine treatment
4
treatment atypical
4
atypical chronic
4
chronic myeloid
4
myeloid leukemia
4
efficacy
1
decitabine
1
treatment
1

Similar Publications

Background: The common drugs used for the treatment of Newly Diagnosed Multiple Myeloma (NDMM) include bortezomib and lenalidomide, but the adverse effects of lenalidomide cannot be ignored, especially when it is used in the initial therapy.

Methods: This retrospective study evaluated the efficacy and safety of a modified DVD regimen (pegylated liposomal doxorubicin, bortezomib, and dexamethasone) followed by lenalidomide in the treatment of NDMM. A total of 40 NDMM patients were treated with a reduced dose of pegylated liposomal doxorubicin (20 mg/m) on day 1, subcutaneous bortezomib (1.

View Article and Find Full Text PDF

Objectives: To determine the safety and efficacy of a video-supported Cawthorne-Cooksey exercise program (CCEP) in improving balance, dizziness and decreasing fear of falling in older adults with balance deficits and dizziness.

Methods: Thirty-two older adults were divided into two groups (intervention and control). The intervention group followed a video-supported CCEP group, while the control group received written instructions to maintain their usual activity and counselling on fall prevention.

View Article and Find Full Text PDF

Background: Primary hyperoxaluria type 1 (PH 1) is a rare genetic condition due to mutations in the AGXT gene. This leads to an overproduction of oxalate in the liver. Hyperoxaluria often causes kidney stones, nephrocalcinosis, and chronic kidney disease.

View Article and Find Full Text PDF

Immuno-oncology in the daily practice.

Curr Opin Oncol

January 2025

Gustave Roussy Departement Interdisciplinaire de Soins de Support aux Patients en Onco-hematologie, Villejuif, France.

Purpose Of Review: Immune checkpoint inhibitors (ICI) have become an integral part of oncology treatment. ICI currently has approval for more than thirty tumor types with proven efficacy. However, ICI can expose patients to inflammatory side effects, such as immuno-related adverse events (irAE).

View Article and Find Full Text PDF

How to monitor the side effects of treatments in cancer patients.

Curr Opin Oncol

January 2025

DIOPP, Gustave Roussy Cancer Campus, Villejuif, France.

Purpose Of Review: Monitoring the side effects of treatments in cancer patients is a key challenge in clinical practice, especially with the development of oral therapies.The impact on patients is multifaceted: morbidity or even life-threatening risks in the case of severe side effects; deterioration in quality of life and functional abilities; lower adherence to treatments; reduced dose intensity, which can affect the efficacy of therapies.

Recent Findings: The availability of digital tools for remote patient monitoring is transforming our ability to track these patients effectively.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!